[HTML][HTML] Acute respiratory distress syndrome
…, M Herridge, AG Randolph, CS Calfee - Nature reviews Disease …, 2019 - nature.com
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema, …
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema, …
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct …
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct …
Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials
CS Calfee, K Delucchi, PE Parsons… - The Lancet …, 2014 - thelancet.com
Background Subphenotypes have been identified within heterogeneous diseases such as
asthma and breast cancer, with important therapeutic implications. We assessed whether …
asthma and breast cancer, with important therapeutic implications. We assessed whether …
A living WHO guideline on drugs for covid-19
…, FAJ Barragan, FJ Bausch, E Burhan, CS Calfee… - 2022 - scholar.sun.ac.za
This living guideline by Arnav Agarwal and colleagues (BMJ 2020; 370: m3379, doi: 10.1136/bmj.
m3379) was last updated on 22 April 2022, but the infographic contained two dosing …
m3379) was last updated on 22 April 2022, but the infographic contained two dosing …
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?
E Fan, JR Beitler, L Brochard, CS Calfee… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic has seen a surge of patients with acute respiratory distress syndrome
(ARDS) in intensive care units across the globe. As experience of managing patients …
(ARDS) in intensive care units across the globe. As experience of managing patients …
Is a “cytokine storm” relevant to COVID-19?
P Sinha, MA Matthay, CS Calfee - JAMA internal medicine, 2020 - jamanetwork.com
In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …
the virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
…, X Fang, K Cosgrove, R Vojnik, CS Calfee… - The Lancet …, 2015 - thelancet.com
Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …
Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy
…, KD Liu, BT Thompson, CS Calfee - American journal of …, 2017 - atsjournals.org
Rationale: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes
in two separate randomized controlled trials with differential response to positive end…
in two separate randomized controlled trials with differential response to positive end…
[HTML][HTML] Redefining critical illness
…, RM Baron, M Bauer, TG Buchman, CS Calfee… - Nature medicine, 2022 - nature.com
Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …
A living WHO guideline on drugs for covid-19
…, FAJ Barragan, FJ Bausch, E Burhan, CS Calfee… - bmj, 2020 - bmj.com
Updates This is the thirteenth version (twelfth update) of the living guideline, replacing earlier
versions (available as data supplements). New recommendations will be published as …
versions (available as data supplements). New recommendations will be published as …